Dehydroepiandrosterone is often marketed like a gentler version of testosterone.
That shortcut is the problem. After menopause, low desire, vaginal dryness, painful sex, fatigue, mood change, and "low hormones" can overlap in one story. They do not all have the same treatment category.
| Product or hormone | Better evidence category | Poor evidence category |
|---|---|---|
| Oral dehydroepiandrosterone supplement | Limited and uncertain menopause-symptom evidence; one low-libido trial did not beat placebo. [1] [2] | Treating low libido, fatigue, or "low hormones" as an automatic supplement indication. |
| Vaginal prasterone, also called vaginal dehydroepiandrosterone | Local genitourinary syndrome of menopause care for moderate to severe painful sex from vulvar and vaginal atrophy. [7] [8] [9] | Treating hot flashes, weight, energy, mood, or whole-body libido. |
| Systemic testosterone | Diagnosed hypoactive sexual desire disorder after assessment, dosing, labs, and monitoring. [3] [4] [5] | Broad "androgen deficiency," anti-aging, cognition, metabolism, or wellness claims. |
Oral DHEA did not beat placebo for low libido in one key trial
A randomized, double-blind trial enrolled 93 postmenopausal women with low libido. They were not using estrogen therapy. Participants received either oral dehydroepiandrosterone 50 mg daily or placebo. [2]
At 26 weeks, 85 women were included in the efficacy analysis. The trial found no significant difference between dehydroepiandrosterone and placebo in total satisfying sexual events per month. It also found no significant difference in sexual self-rating, well-being, or menopause quality-of-life scores. [2]
The trial also reported more androgenic effects, including acne and increased hair growth, in the dehydroepiandrosterone group. [2]
That is not a blanket rule that every dehydroepiandrosterone product is useless. It is a reason not to sell oral dehydroepiandrosterone as an easy testosterone alternative for postmenopausal low desire.
Reviews leave DHEA in a cautious category
A Cochrane review of dehydroepiandrosterone for peri- or postmenopausal women found no evidence that dehydroepiandrosterone improved quality of life. It found some evidence of androgenic side effects. It also found uncertainty around menopause symptoms. Sexual-function effects were small and should be read cautiously. [1]
Dehydroepiandrosterone requires that uncertainty. A careful answer should not imply that a low dehydroepiandrosterone sulfate lab automatically confirms a supplement need. It should not imply that over-the-counter dehydroepiandrosterone is safer because it is sold outside prescription channels.
Testosterone has a narrower evidence category
The Global Consensus Position Statement says the only evidence-based indication for systemic testosterone therapy in women is hypoactive sexual desire disorder after formal assessment. [3]
The International Society for the Study of Women's Sexual Health guideline gives clinical practice details for systemic testosterone use in women with hypoactive sexual desire disorder. It covers diagnosis, dosing, monitoring, and avoiding high testosterone exposure. [4]
That is a different category from oral dehydroepiandrosterone. It is also different from vague "androgen deficiency" marketing.
A 2019 systematic review and meta-analysis of testosterone for women included 46 reports of 36 randomized controlled trials with 8,480 participants. Compared with placebo or comparator, testosterone increased satisfactory sexual event frequency by a mean 0.85 events, sexual desire by standardized mean difference 0.36, arousal by 0.28, orgasm by 0.25, and responsiveness by 0.28. [5]
That benefit is real but bounded. It applies to sexual function outcomes, not to a general midlife reset. It also does not remove monitoring. The International Society for the Study of Women's Sexual Health guideline says systemic transdermal testosterone is recommended for women with hypoactive sexual desire disorder not primarily related to modifiable factors or comorbidities, and it notes that long-term safety data are limited. [4]
| Testosterone question | Stronger answer | Weaker answer |
|---|---|---|
| Main symptom | Low desire with distress after pain, medication, mood, sleep, relationship, and medical contributors are reviewed. [4] | Fatigue, brain fog, weight gain, hair loss, or "low T" on a lab alone. |
| Evidence | Moderate benefit for sexual-function outcomes in randomized controlled trials. [5] | Claims of broad energy, metabolism, cognition, or longevity benefit. |
| Safety | Female-range dosing, baseline total testosterone, monitoring, and review for acne, hair growth, scalp shedding, voice, clitoral, lipid, and liver concerns. [4] | Pellets, high-dose injections, or dose escalation based on feeling "optimized." |
| Conversion fit | Clinician-led hypoactive sexual desire disorder and medication review. | Self-directed androgen stacking with dehydroepiandrosterone. |
Vaginal and urinary symptoms usually need a local symptom pathway first
Genitourinary syndrome of menopause includes vaginal dryness, burning, irritation, urinary symptoms, and painful sex. The 2020 Menopause Society genitourinary syndrome of menopause statement reviews options such as moisturizers, lubricants, vaginal estrogen, vaginal dehydroepiandrosterone/prasterone, ospemifene, and pelvic-floor or specialty care. [6]
This distinction matters for conversion. A woman whose main complaint is pain with sex may need genitourinary syndrome of menopause evaluation before anyone considers systemic testosterone. A woman whose main issue is absent desire with distress may need hypoactive sexual desire disorder assessment. Some women need both.
Prasterone is the clearest reason not to use the word dehydroepiandrosterone loosely. INTRAROSA is a 6.5 mg prasterone vaginal insert used once daily at bedtime for moderate to severe dyspareunia from vulvar and vaginal atrophy due to menopause. [7]
In a 12-week phase III trial, 6.5 mg intravaginal dehydroepiandrosterone improved pain with sexual activity by 1.42 severity-score units from baseline, or 0.36 units more than placebo, and improved vaginal dryness by 1.44 units from baseline, or 0.27 units more than placebo. [8] A 2026 meta-analysis of six randomized controlled trial reports representing five unique randomized trials with 1,611 postmenopausal women found intravaginal dehydroepiandrosterone improved vaginal dryness and dyspareunia versus placebo. [9]
That does not rescue oral dehydroepiandrosterone supplement claims. It means route and diagnosis matter. Vaginal prasterone is a local genitourinary syndrome of menopause treatment; oral dehydroepiandrosterone is not established to be a testosterone substitute for low desire.
Decision table: which category does the symptom belong in?
| Main concern | Better next question | What not to assume |
|---|---|---|
| Low desire with personal distress | Is this hypoactive sexual desire disorder after medication, mood, pain, sleep, relationship, and medical contributors are reviewed? | That oral dehydroepiandrosterone is an easier version of testosterone. |
| Vaginal dryness, burning, or painful sex | Is genitourinary syndrome of menopause present, and would local treatment fit before systemic testosterone? | That low desire is the primary problem when sex hurts. |
| Fatigue, brain fog, or weight gain | What non-androgen causes need evaluation first? | That testosterone or dehydroepiandrosterone treats nonspecific midlife symptoms. |
| Acne, hair growth, or scalp shedding | Is androgen excess, polycystic ovary syndrome history, medication exposure, thyroid disease, iron deficiency, or another cause present? | That adding dehydroepiandrosterone is safe when androgenic signs already exist. |
| Interest in over-the-counter oral dehydroepiandrosterone | What evidence, side effects, product quality, and lab context support or argue against it? | That supplement availability means medical safety. |
Who this fits
This comparison fits a woman who has been told that dehydroepiandrosterone, testosterone, vaginal prasterone, and "androgen deficiency" are the same problem. It is also useful when low desire and painful sex are happening together, because pain can suppress desire and genitourinary syndrome of menopause can need treatment before anyone judges testosterone response.
It is a poor fit for self-directed dosing. Over-the-counter dehydroepiandrosterone can still cause androgenic effects, and systemic testosterone should stay tied to diagnosed hypoactive sexual desire disorder, female-range exposure, and monitoring.
Red flags before taking androgen claims seriously
Pause before dehydroepiandrosterone or testosterone if there is unexplained vaginal bleeding, new pelvic pain, vulvar lesions, breast cancer history, pregnancy potential, severe acne or hirsutism, voice change, clitoral enlargement, scalp hair loss, abnormal liver tests, complex cardiovascular risk, or use of products that cannot be dose-verified.
This is especially important with compounded hormone programs, pellets, and injection plans that combine testosterone, dehydroepiandrosterone, estrogen, progesterone, or other hormones. More hormones can make it harder to tell what is helping, what is causing side effects, and what should be stopped.
What to ask a clinician
Ask:
- Is my main problem hypoactive sexual desire disorder, genitourinary syndrome of menopause, pain, fatigue, mood, medication effect, or more than one?
- Does oral dehydroepiandrosterone have evidence for my symptom target, or is that a marketing shortcut?
- Would vaginal estrogen, prasterone, ospemifene, moisturizer, pelvic-floor care, or testosterone better match the diagnosis?
- What side effects should stop dehydroepiandrosterone or testosterone, especially acne, hair growth, scalp shedding, or voice change?
- What labs and follow-up would prevent supraphysiologic androgen exposure?
Bottom line
The useful article is not "dehydroepiandrosterone vs testosterone: which is better?" The better question is: what symptom are we treating?
Low desire with distress, vaginal dryness, painful sex, fatigue, hair growth, acne, and lab values all point to different next steps. Clinician-led care should route the reader into a clinical review that separates hypoactive sexual desire disorder, genitourinary syndrome of menopause, medication effects, relationship context, mood, sleep, metabolic risk, and contraindications.
If the main problem is low desire with distress, testosterone may be a structured hypoactive sexual desire disorder conversation. If the main problem is painful sex or dryness, genitourinary syndrome of menopause care may come first. If the main pitch is oral dehydroepiandrosterone for whole-body optimization, the evidence is limited and the side-effect discussion should get louder.
Related reading:
- Low Testosterone Symptoms in Women After Menopause.
- Testosterone and Breast Cancer Risk After Menopause.
- Testosterone and Hair Loss After Menopause.
- Prasterone After Menopause.
- Testosterone Side Effects in Women.
References
[1] Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev. 2015;1(1):CD011066. doi:10.1002/14651858.cd011066.pub2 https://pubmed.ncbi.nlm.nih.gov/25879093/
[2] Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med. 2009;6(9):2579-90. doi:10.1111/j.1743-6109.2009.01381.x https://pubmed.ncbi.nlm.nih.gov/19619146/
[3] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[4] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009 https://pubmed.ncbi.nlm.nih.gov/33814355/
[5] Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/s2213-8587(19)30189-5 https://pubmed.ncbi.nlm.nih.gov/31353194/
[6] The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi:10.1097/gme.0000000000001609 https://pubmed.ncbi.nlm.nih.gov/32852449/
[7] DailyMed. INTRAROSA prasterone insert prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df731acd-7276-4fef-b037-bc7f30c112cb
[8] Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2018;25(11):1339-1353. doi:10.1097/gme.0000000000001238 https://pubmed.ncbi.nlm.nih.gov/30358731/
[9] Lemos MJ, Queiroz LF, Diniz AF, et al. Intravaginal dehydroepiandrosterone for the treatment of vulvovaginal atrophy: a systematic review and meta-analysis. Menopause. 2026;33(7):852-858. doi:10.1097/gme.0000000000002736 https://pubmed.ncbi.nlm.nih.gov/41589851/